ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 17.95 USD 2.05% Market Closed
Market Cap: 1.8B USD

Operating Margin
ARS Pharmaceuticals Inc

-27.9%
Current
-66 776.8%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-27.9%
=
Operating Profit
-27.1m
/
Revenue
97.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
ARS Pharmaceuticals Inc
NASDAQ:SPRY
1.8B USD
-28%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
335.8B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
141.5B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.8B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

ARS Pharmaceuticals Inc
Glance View

In the competitive landscape of biotechnology, ARS Pharmaceuticals Inc. positions itself as a transformative player with a focused mission to innovate life-saving medical treatments. The company concentrates on the development of novel therapeutics aimed at treating severe and life-threatening allergic reactions. Its flagship product, a nasal spray designed to deliver epinephrine quickly and effectively, stands as a testament to its innovative efforts. By channeling resources into this potentially groundbreaking delivery mechanism, ARS Pharmaceuticals seeks to address the critical need for patient-friendly solutions in emergency situations, where traditional methods like auto-injectors may be less ideal. Through relentless research and strategic development, the company aims to make these treatments more accessible and user-friendly, potentially expanding their reach within the healthcare market. ARS Pharmaceuticals generates revenue through the commercialization of its therapies, primarily targeting the lucrative segments associated with allergy treatments. Key to their financial strategy is securing regulatory approvals, which opens pathways for product launches and subsequent revenue channels. Furthermore, leveraging strategic partnerships and collaborations within the pharmaceutical industry enhances their market presence. Such alliances allow ARS Pharmaceuticals to tap into established distribution networks, maximizing both reach and revenue potential. Their business model underscores a commitment not only to innovation but also to scalability, aiming to establish a sustainable revenue stream as the demand for efficient allergy treatments grows. This strategic positioning reflects a thorough understanding of market needs and a keen ability to adapt to the ever-evolving healthcare landscape.

SPRY Intrinsic Value
18.64 USD
Undervaluation 4%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-27.9%
=
Operating Profit
-27.1m
/
Revenue
97.1m
What is the Operating Margin of ARS Pharmaceuticals Inc?

Based on ARS Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -27.9%.

Back to Top